Andy Chen
Stock Analyst at Wolfe Research
(3.52)
# 900
Out of 5,081 analysts
42
Total ratings
52%
Success rate
32.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Downgrades: Peer Perform | n/a | $921.80 | - | 3 | Nov 24, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Peer Perform | n/a | $9.06 | - | 3 | Nov 12, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $21.25 | - | 1 | Nov 6, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Peer Perform | n/a | $54.69 | - | 2 | Oct 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $473.29 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $41.26 | - | 2 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $74.15 | -33.92% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $21.84 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $71.58 | -23.16% | 1 | Jun 17, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $13.35 | +356.93% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $43.76 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $46.98 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $29.60 | -32.43% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $36.67 | -48.19% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $22.71 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $101.50 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $27.81 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $65.99 | -1.50% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $579.89 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $31.28 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $32.06 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $81.84 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $55.99 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $20.70 | -17.87% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $463.13 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $206.78 | -79.69% | 1 | Feb 15, 2024 |
argenx SE
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $921.80
Upside: -
Intellia Therapeutics
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $9.06
Upside: -
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $21.25
Upside: -
Akero Therapeutics
Oct 10, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $54.69
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $473.29
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $41.26
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $74.15
Upside: -33.92%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $21.84
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $71.58
Upside: -23.16%
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $13.35
Upside: +356.93%
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $43.76
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $46.98
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $29.60
Upside: -32.43%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $36.67
Upside: -48.19%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $22.71
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $101.50
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $27.81
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $65.99
Upside: -1.50%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $579.89
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $31.28
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $32.06
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $81.84
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $55.99
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $20.70
Upside: -17.87%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $463.13
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $206.78
Upside: -79.69%